Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma
NCT00054834 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27
Last updated 2021-08-16
Summary
The purpose of this trial is to determine the safety of 90Y-hLL2 at different dose levels in the treatment of Non-Hodgkin's lymphoma.
Conditions
- Non-Hodgkins Lymphoma
Interventions
- DRUG
-
hLL2 (epratuzumab)
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-03-31
Countries
- United States
Study Locations
More Related Trials
-
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
NCT00481832 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
NCT01101581 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
NCT01116154 ·Status: TERMINATED ·Phase: PHASE1
-
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT00989586 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma
NCT00003575 ·Status: COMPLETED ·Phase: PHASE2
-
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease
NCT00003210 ·Status: COMPLETED ·Phase: PHASE2
-
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
NCT00096460 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL
NCT01585688 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00054808 ·Status: COMPLETED ·Phase: PHASE2
-
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
NCT00042913 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma
NCT03120676 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
NCT01147393 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
NCT02875067 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
NCT02332980 ·Status: COMPLETED ·Phase: PHASE2
-
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
NCT00720876 ·Status: COMPLETED ·Phase: PHASE2
-
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
NCT06723457 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
NCT02911142 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
NCT00005950 ·Status: TERMINATED ·Phase: PHASE2
-
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00014664 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma
NCT03465891 ·Status: TERMINATED ·Phase: PHASE2
-
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
NCT01032148 ·Status: TERMINATED ·Phase: PHASE1
-
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
NCT01088048 ·Status: COMPLETED ·Phase: PHASE1
-
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
NCT02568553 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00032019 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
NCT02453594 ·Status: COMPLETED ·Phase: PHASE2